GSK's new drug brings hope of completely curing rectal cancer.
Global biopharmaceutical company GSK has just announced impressive results from phase 2 clinical trials of a new drug called Jemperli (dostarlimab). In this trial, Jemperli demonstrated incredible effectiveness in treating rectal cancer.
Jemperli is expected to open a new future for rectal cancer treatment.
Accordingly, all 42 patients participating in the trial achieved complete clinical remission with no signs of tumor after treatment with Jemperli. In particular, among 24 patients followed for an average of 26.3 months, there was no case of cancer recurrence.
Jemperli is a monoclonal antibody drug that works by activating the body's immune system to kill cancer cells. This drug is expected to replace current standard treatments, including chemotherapy, radiotherapy and surgery, which cause many side effects and negatively affect patients' quality of life.
GSK said it will continue to study Jemperli in additional trials with other types of colorectal cancer. Although not yet widely approved worldwide, these promising results have opened a new direction in rectal cancer treatment, bringing hope to millions of patients globally.
